Phase I Trial of Etoposide, Doxorubicin and Cisplatin (EAP) in Combination with GM-CSF

European Journal of Cancer

Volumn 32, Issue 4, 1996, Pages 631-635

  Ford, P A ^a   Arbuck, S G ^b   Minniti, C ^a   Miller, L L ^c   Demaria, D ^a   O'Dwyer, P J ^a,c  

^a FOX CHASE CANCER CENTER   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cisplatin; Doxorubicin; Etoposide; GM CSF; Phase I trial

Indexed keywords

CISPLATIN; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG TOXICITY; DYSPNEA; FEMALE; HEART ARRHYTHMIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; ETOPOSIDE; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; RECOMBINANT PROTEINS; THROMBOCYTOPENIA;

EID: 0029889594     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(95)00602-8     Document Type: Article

References (33)

1. Boring CC, Squires TS, Tong T. Cancer statistics. CA Cancer J Clin 1992,42, 19-38.
2. Macdonald JS, Steele G Jr, Gunderson LL. Cancer of the stomach. In DeVita VT Jr, Hellman S, Rosenberg S, eds. Cancer Principles and Practice of Oncology, Vol. 1, 3rd edn. Philadelphia, JB Lippincott, 1989, 765-797.
3. Macdonald JS, Schein PS, Wooley PV, et al. 5-fluorouracil, doxorubicin and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. Ann Intern Med 1980, 93, 533-536.
4. Preusser H, Wilke H, Achterrath W, et al. Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J Clin Oncol 1989, 7, 1310-1317.
5. Katz A, Gansl A, Simon SD, Gama-Rodriques J, Waitzberg D, Bresciani CJ. Phase II trial of VP16, adriamycin and cisplatin in patients with metastatic gastric cancer. J Clin Oncol 1991, 14, 357-358.
6. Sparano J, Schwartz E, Salva K, Strack M, Wiernik PH. Severe myelotoxicity associated with etoposide (VP16), adriamycin (A), and cisplatin (DDP) in the treatment of advanced gastric cancer. Proc Am Assoc Cancer Res 1989, 30, 257.
7. Taguchi T. Combination chemotherapy with etoposide (E), adriamycin (A) and cisplatin (P) (EAP) for advanced gastric cancer. Proc Am Soc Clin Oncol 1989, 8, 108.
8. Metcalf D, Burgess AW. Clonal analysis of progenitor cell commitment to granulocyte or macrophage production. J Cell Physiol 1982, 111, 275-283.
9. Metcalf D, Merchav S. Effects of GM-CSF deprivation on precursors of granulocyte and macrophages. J Cell Physiol 1982, 112, 411-418.
10. Brandt SJ, Peter WP, Atwater SK et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N Engl J Med 1988, 318, 869-876.
11. Gianni AM, Bregni M, Siena S, et al. Recombinant human granulocyte-macrophage colony-stimulating factor reduces hematologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkins lymphoma. J Clin Oncol 1990, 8, 768-778.
12. Leieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. N Engl J Med 1992, 327, 99-106.
13. Hoekman K, Wagstaff J, van Groeningen CJ, Vermorken JB, Boven E, Pinedo HE. Effects of recombinant human granulocyte-macrophage colony-stimulating factor on myelosuppression induced by multiple cycles of high dose chemotherapy in patients with advanced breast cancer. J Natl Cancer Inst 1991, 83, 1546-1553.
14. Logothetis G, Dexeus F, Sella A, et al. Escalated therapy for refractory urothelial tumors: methotrexate-vinblastin-doxorubicin-cisplatin plus unglycosylated recombinant human granulocyte-macrophage colony stimulating factor. J Natl Cancer Inst 1990, 82, 667-672.
15. Rowe JM, Anderson J, Mazza JJ, Paietta E, Bennett JM, Wiernik PH. Phase III randomized placebo-controlled study of yeast derived GM-CSF in adult patients (55-70 years) with AML. Blood 1993, 82, Suppl. 1, 329a (abstract).
16. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981, 47, 207-214.
17. Neidhart JA, Mangalik A, Stidley CA, et al. Dosing regimen of granulocyte-macrophage colony-stimulating factor to support dose-intensive chemotherapy. J Clin Oncol 1992, 10, 1460-1469.
18. Shaffer D, Higashi L, Bums H, et al. A Phase I trial of combined oral etoposide (VP16) and granulocyte-macrophage colony stimulating factor (GM-CSF). Proc Am Soc Clin Oncol 1993, 12, 155 (abstract).
19. Kaplan LD, Kahn JO, Crowe F, et al. Clinical and virologic effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: results of a randomized trial. J Clin Oncol 1991, 9, 929-940.
20. Kelsen D, Atiq OT, Saltz L, et al. FAMTX versus etoposide, doxorubicin and cisplatin. A random assignment trial in gastric cancer. J Clin Oncol 1992, 4, 541-548.
21. Lerner A, Coonin R, Steele GD, Mayer RJ. Etoposide, doxorubicin, cisplatin for advanced gastric adenocarcinoma: results of a Phase II trial. J Clin Oncol 1992, 10, 536-540.
22. deVries EGE, Biesma B, Willemze PHB, et al. A double-blind placebo controlled study with granulocyte-macrophage colony-stimulating factor during chemotherapy for ovarian carcinoma. Cancer Res 1991, 51, 116-122.
23. Neidhart JA. Dose intensive treatment of breast cancer supported by granulocyte macrophage colony-stimulating factor. Breast Cancer Res 1991, 20, 515-523.
24. Neumunaitis J, Rabinowe SN, Singer JW, et al. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 1991, 324, 1773-1778.
25. Crawford J, Oze RH, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small cell lung cancer. N Engl J Med 1991,325, 164-170.
26. Petros WP, Peters WP. Hematopoietic colony-stimulating factors and dose intensity. Semin Oncol 1993, 20, 94-99.
27. Rosenfield CS, Neumunaitis J. The role of granulocyte-macrophage colony-stimulating factor-stimulating progenitor cells in oncology. Semin Hematol 1992, 29, 19-26.
28. Herrmann F, Schulz G, Lindemann A, et al. Hematopoietic responses in patients with advanced malignancy treated with recombinant human granulocyte-macrophage colony-stimulating factor. J Clin Oncol 1989, 7, 159-167.
29. Shadduck RK. Granulocyte-macrophage colony-stimulating factor: present status. Semin Hematol 1992, 29, 1-41.
30. Socinski MA, Cannista JA, Elias A, Antman KH, Schnipper L, Griffin JD. Granulocyte-macrophage colony-stimulating factor expands the circulating hematopoietic progenitor cell compartment in men. Lancet 1988, i, 1194-1198.
31. Meropol NJ, Miller LL, Korn EL, Braitman LE, MacDermott ML, Schuchter LM. Severe myelosuppression resulting from concurrent administration of granulocyte colony-stimulating factor and cytotoxic chemotherapy. J Natl Cancer Inst 1992, 84, 1201-1203.
32. Rowinsky E, Sartorius S, Grochow L, et al. Phase I and pharmacologic study of topotecan, an inhibitor of topoisomerase I, with granulocyte colony-stimulating factor (G-CSF): toxicologic differences between concurrent and post-treatment G-CSF administration. Proc Am Soc Clin Oncol 1992, 11, 116 (abstract).
33. Shaffer D, Smith L, Burns H, et al. A randomized Phase I trial of VP-16 and GM-CSF in patients with advanced solid tumors. Proc Am Assoc Cancer Res 1992, 33, 243 (abstract).